好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

An Update on the First U.S. Treatment Trial for Sporadic Jakob-Creutzfeldt Disease (sCJD)
Aging and Dementia
(-)
002
Authors/Disclosures
Michael D. Geschwind, MD, PhD, FAAN (UCSF) Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Benjamin Raudabaugh (UCSF) No disclosure on file
Aissatou Haman No disclosure on file
Holli A. Horak, MD, FAAN (University of Arizona) Dr. Horak has received personal compensation in the range of $0-$499 for serving as a Grant Reviewer with FDA. Dr. Horak has a non-compensated relationship as a Finance Committee member with AANEM that is relevant to AAN interests or activities.
Gillian Devereux No disclosure on file
No disclosure on file
Charles Torres-Chae (University of California San Francisco) No disclosure on file
Amy Kuo No disclosure on file
Bruce L. Miller, MD, FAAN (University of California, San Francisco) Dr. Miller has nothing to disclose.